A whole-cell inactivated vaccine for improved protection against tuberculosis
Active Project Grant Awarded Last action
- Award ID
- R41AI186746
- Recipient
-
Solaris Vaccines, Inc. UEI G1P5NEDCERA9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $543,876
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 62% complete
- Place of performance
- Fort Collins, CO 80521, USA
Award details come from USAspending.gov.
Description
- Abstract
- Tuberculosis (TB), caused by mycobacterium tuberculosis (MTB), is the world's deadliest infectious disease. Approximately 10.6 million people fell ILL from TB in 2022, resulting in 1.6 million deaths GLOBALLY1. These alarming numbers demonstrate the critical need for effective TB prevention and treatment worldwide. The commercially available vaccine bacille calmette guérin (BCG) effectively prevents systemic infection that occurs in children, but poorly protects against the more common pulmonary infection in adults. Additionally, BCG does not elicit mucosal immunity in the lungs, which is a major reason BCG vaccination does not protect adults adequately. We have developed solavax-TB, a whole-cell inactivated MTB vaccine, to address the significant unmet need for a scalable and cost-effective vaccine that triggers both systemic and pulmonary immunity. Solavax-TB is created using the photosensitizer riboflavin (vitamin B2) and ultraviolet (UV) light to disrupt pathogen genetic material while preserving antigenic integrity. Solavax-TB shows in vivo efficacy as a BCG booster when administered both intramuscularly (IM; systemic immunity) or intranasally (in; mucosal/lung immunity; FIG. 2). In new preliminary data, we now show significant long-term (up to 90 days) pulmonary protection by in solavax-TB delivered in combination with the potent mucosal adjuvant mucosimmune (nanoparticle liposomal-dual TLR complexes) following initial BCG prime vaccination (FIG. 3). Here, we will evaluate the safety, immunogenicity, and efficacy of mucosal solavax-TB. Aim 1 will test our vaccine against alternative whole-cell vaccine candidates. Aim 2 will evaluate the long-term protective efficacy of in solavax-TB as a boost for conventional BCG vaccination and as a stand-alone vaccine against pulmonary challenge with high-virulence MTB. Collectively, these studies will provide the basis for furthering development of solavax-TB toward IND and ultimately, the clinic.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $274,002 | |
| Original award | $269,874 |
Quick answers
Who received award R41AI186746?
R41AI186746 was awarded to Solaris Vaccines, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2025.
How much is award R41AI186746 worth?
$543,876 has been obligated on R41AI186746.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award